Healthcare company Organon & Co. (OGN) said on Wednesday that it is discontinuing the development of its investigational ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma ...

Organon said on Wednesday it will the stop development of an experimental treatment it acquired through its purchase of Forendo Pharma, after the drug failed to reduce pelvic pain in women with ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational candidate OG-6219 in ...

The Global Endometriosis Treatment Market is expected to reach at a CAGR of 10.62% during the forecast period 2025-2033. Sai Kiran DataM Intelligence 4Market Research +1 877-441-4866 ... Visit us on ...

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

A major umbrella review shows that higher intake of vegetables and dairy products is linked to a lower risk of endometriosis, ...

Endometriosis impacts daily functioning because of the intense cramps. Know how yoga may help support the pain.

A study found that a low FODMAP diet significantly reduced gastrointestinal symptoms such as abdominal pain and bloating in ...